ATE260295T1 - Peptidfragmente von mikrobiellen stressproteinen und daraus hergestellte pharmazeutische zusammensetzungen für die behandlung und vorbeugung von entzündungserkrankungen - Google Patents
Peptidfragmente von mikrobiellen stressproteinen und daraus hergestellte pharmazeutische zusammensetzungen für die behandlung und vorbeugung von entzündungserkrankungenInfo
- Publication number
- ATE260295T1 ATE260295T1 AT95912506T AT95912506T ATE260295T1 AT E260295 T1 ATE260295 T1 AT E260295T1 AT 95912506 T AT95912506 T AT 95912506T AT 95912506 T AT95912506 T AT 95912506T AT E260295 T1 ATE260295 T1 AT E260295T1
- Authority
- AT
- Austria
- Prior art keywords
- aminoacids
- microbial
- treatment
- peptides
- mammalian
- Prior art date
Links
- 102000002812 Heat-Shock Proteins Human genes 0.000 title abstract 4
- 108010004889 Heat-Shock Proteins Proteins 0.000 title abstract 4
- 230000000813 microbial effect Effects 0.000 title abstract 4
- 208000027866 inflammatory disease Diseases 0.000 title abstract 2
- 108010033276 Peptide Fragments Proteins 0.000 title 1
- 102000007079 Peptide Fragments Human genes 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 235000001014 amino acid Nutrition 0.000 abstract 5
- 150000001413 amino acids Chemical class 0.000 abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 206010052779 Transplant rejections Diseases 0.000 abstract 1
- 230000002917 arthritic effect Effects 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000028709 inflammatory response Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 206010028417 myasthenia gravis Diseases 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP94200721 | 1994-03-21 | ||
EP94200738 | 1994-03-22 | ||
EP94202927 | 1994-10-10 | ||
PCT/NL1995/000108 WO1995025744A1 (en) | 1994-03-21 | 1995-03-21 | Peptide fragments of microbial stress proteins and pharmaceutical composition made thereof for the treatment and prevention of inflammatory diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE260295T1 true ATE260295T1 (de) | 2004-03-15 |
Family
ID=27235971
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT95912506T ATE260295T1 (de) | 1994-03-21 | 1995-03-21 | Peptidfragmente von mikrobiellen stressproteinen und daraus hergestellte pharmazeutische zusammensetzungen für die behandlung und vorbeugung von entzündungserkrankungen |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP0751957B1 (de) |
JP (2) | JPH09511239A (de) |
AT (1) | ATE260295T1 (de) |
AU (1) | AU699007B2 (de) |
CA (1) | CA2185826C (de) |
DE (1) | DE69532605T2 (de) |
DK (1) | DK0751957T3 (de) |
ES (1) | ES2216009T3 (de) |
PT (1) | PT751957E (de) |
WO (1) | WO1995025744A1 (de) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9419553D0 (en) * | 1994-09-27 | 1994-11-16 | Univ Bristol | Polypeptides and their use in the treatment of auto-immune disease |
GB9519737D0 (en) * | 1995-09-27 | 1995-11-29 | Peptide Therapeutics Ltd | Polypeptides and their use in treatment and prophylaxis of auto-immune |
US6284255B1 (en) * | 1996-08-29 | 2001-09-04 | Genesis Research & Development Corporation Limited | Compounds and methods for treatment and diagnosis of mycobacterial infections |
US5985287A (en) * | 1996-08-29 | 1999-11-16 | Genesis Research And Development Corporation Limited | Compounds and methods for treatment and diagnosis of mycobacterial infections |
US5968524A (en) * | 1997-12-23 | 1999-10-19 | Genesis Research & Development Corp. | Methods and compounds for the treatment of immunologically-mediated psoriasis |
EP0947524A1 (de) * | 1998-03-30 | 1999-10-06 | Upither B.V. | Neue Peptide zur Behandlung von Autoimmunkrankheiten |
IL126447A (en) * | 1998-10-04 | 2004-09-27 | Vascular Biogenics Ltd | An immune preparation that confers tolerance in oral administration and its use in the prevention and / or treatment of atherosclerosis |
US7488476B2 (en) | 1998-11-05 | 2009-02-10 | Hadasit Medical Research Services & Development Ltd. | B-cell epitope peptides of HSP 65, DNA encoding said peptides, antibodies directed against said peptides and the different uses thereof in the treatment of inflammatory and autoimmune diseases |
US8158125B2 (en) | 1998-11-05 | 2012-04-17 | Hadasit Medical Research Services & Development Ltd. | B-cell epitope peptides of HSP 65, novel amino acid sequences, DNA encoding the amino acid sequences of said peptides, antibodies directed against said peptides and different uses thereof in the treatment of inflammatory and autoimmune diseases |
DE69929454T2 (de) | 1998-11-05 | 2006-09-28 | Hadasit Medical Research Services & Development Co. Ltd. | Neue aminosäuresequenzen, deren kodierende dns, antikörper dagegen und deren verwendungen |
AU3239400A (en) * | 1999-02-22 | 2000-09-04 | University Of Iowa Research Foundation, The | Method for inhibiting inflammatory responses |
IL132611A0 (en) | 1999-10-27 | 2001-03-19 | Yeda Res & Dev | Synthetic genes and polypeptides and pharmaceutical compositions comprising them |
US6812205B2 (en) | 2000-03-15 | 2004-11-02 | The Brigham & Women's Hospital, Inc. | Suppression of vascular disorders by mucosal administration of heat shock protein peptides |
EP1652856A1 (de) * | 2000-08-09 | 2006-05-03 | The Regents of The University of California San Diego | Stressproteine-abgeleitete Peptide und Verfahren zu deren Verwendung |
US7608683B2 (en) | 2000-08-09 | 2009-10-27 | The Regents Of The University Of California | Stress proteins and peptides and methods of use thereof |
US6989146B2 (en) * | 2000-08-09 | 2006-01-24 | The Regents Of The University Of California | Stress proteins and peptides and methods of use thereof |
GB0028122D0 (en) * | 2000-11-17 | 2001-01-03 | St Georges Entpr Ltd | Method |
EP1575479A4 (de) | 2002-01-31 | 2006-10-25 | Develogen Israel Ltd | Hsp-peptide und analoga zur modulation von immunantworten über antigen präsentierende zellen |
WO2006072946A2 (en) | 2005-01-04 | 2006-07-13 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Hsp60, hsp60 peptides and t cell vaccines for immunomodulation |
CN101801402B (zh) | 2007-07-06 | 2013-08-28 | 乌得勒支大学控股有限公司 | 炎性疾病和自身免疫疾病的治疗和预防 |
CA2728363C (en) | 2008-06-26 | 2019-02-19 | Orphazyme Aps | Use of hsp70 as a regulator of enzymatic activity |
JP5350996B2 (ja) * | 2009-11-25 | 2013-11-27 | バブコック日立株式会社 | 酸素燃焼システムの排ガス処理装置 |
AU2011335545A1 (en) | 2010-11-30 | 2013-06-13 | Orphazyme Aps | Methods for increasing intracellular activity of Hsp70 |
PT3193840T (pt) | 2014-09-15 | 2021-08-10 | Orphazyme Aps | Formulação de arimoclomol |
EP3442530A1 (de) | 2016-04-13 | 2019-02-20 | Orphazyme A/S | Hitzeschockproteinen und cholesterinhomöostase |
KR102254140B1 (ko) | 2016-04-29 | 2021-05-24 | 오르파짐 에이/에스 | 글루코세레브로시다제 연관 장애를 치료하기 위한 아리모클로몰 |
EP4247792A1 (de) | 2020-11-19 | 2023-09-27 | Zevra Denmark A/S | Verfahren zur herstellung von arimoclomolcitrat und zwischenprodukten davon |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL8701163A (nl) * | 1986-09-09 | 1988-04-05 | Nederlanden Staat | Gebruik van een peptide voor de bereiding van preparaten voor het verlichten, het behandelen en de diagnose van autoimmuunziekten, in het bijzonder arthritische toestanden, verbindingen die met dit peptide verwant zijn, alsmede farmaceutische en diagnostische preparaten en testkits. |
US4952395A (en) * | 1987-02-26 | 1990-08-28 | Scripps Clinic And Research Foundation | Mycobacterial recombinants and peptides |
NL8703107A (nl) * | 1987-12-22 | 1989-07-17 | Nederlanden Staat | Polypeptiden en derivaten daarvan, alsmede de toepassing daarvan in farmaceutische en diagnostische preparaten. |
US5114844A (en) * | 1989-03-14 | 1992-05-19 | Yeda Research And Development Co., Ltd. | Diagnosis and treatment of insulin dependent diabetes mellitus |
WO1992004049A1 (en) * | 1990-09-06 | 1992-03-19 | Rijksuniversiteit Te Utrecht | Inhibitor of lymphocyte response and immune-related disease |
-
1995
- 1995-03-21 AT AT95912506T patent/ATE260295T1/de not_active IP Right Cessation
- 1995-03-21 DE DE69532605T patent/DE69532605T2/de not_active Expired - Fee Related
- 1995-03-21 CA CA002185826A patent/CA2185826C/en not_active Expired - Fee Related
- 1995-03-21 DK DK95912506T patent/DK0751957T3/da active
- 1995-03-21 PT PT95912506T patent/PT751957E/pt unknown
- 1995-03-21 WO PCT/NL1995/000108 patent/WO1995025744A1/en active IP Right Grant
- 1995-03-21 JP JP7524557A patent/JPH09511239A/ja active Pending
- 1995-03-21 AU AU19628/95A patent/AU699007B2/en not_active Ceased
- 1995-03-21 ES ES95912506T patent/ES2216009T3/es not_active Expired - Lifetime
- 1995-03-21 EP EP95912506A patent/EP0751957B1/de not_active Expired - Lifetime
-
2006
- 2006-08-09 JP JP2006217557A patent/JP2007000147A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
DE69532605T2 (de) | 2005-02-17 |
DE69532605D1 (de) | 2004-04-01 |
AU699007B2 (en) | 1998-11-19 |
DK0751957T3 (da) | 2004-06-01 |
CA2185826C (en) | 2007-06-19 |
AU1962895A (en) | 1995-10-09 |
EP0751957A1 (de) | 1997-01-08 |
WO1995025744A1 (en) | 1995-09-28 |
EP0751957B1 (de) | 2004-02-25 |
CA2185826A1 (en) | 1995-09-28 |
ES2216009T3 (es) | 2004-10-16 |
PT751957E (pt) | 2004-07-30 |
JPH09511239A (ja) | 1997-11-11 |
JP2007000147A (ja) | 2007-01-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE260295T1 (de) | Peptidfragmente von mikrobiellen stressproteinen und daraus hergestellte pharmazeutische zusammensetzungen für die behandlung und vorbeugung von entzündungserkrankungen | |
Atoda et al. | The primary structure of coagulation factor IX/factor X-binding protein isolated from the venom of Trimeresurus flavoviridis. Homology with asialoglycoprotein receptors, proteoglycan core protein, tetranectin, and lymphocyte Fc epsilon receptor for immunoglobulin E | |
Hood et al. | Light chain evolution | |
Hirabayashi et al. | Complete primary structure of a galactose-specific lectin from the venom of the rattlesnake Crotalus atrox. Homologies with Ca2 (+)-dependent-type lectins | |
ATE108662T1 (de) | Antimikrobielle peptide, zusammensetzungen, die diese enthalten, und verwendungen daraus. | |
PT93910A (pt) | Prodesso para a preparacao de uma proteina heterologa mediante secrecao a partir de uma celula | |
DE69934967D1 (de) | Verfahren zur verminderung der immunogenität von proteinen | |
ATE183514T1 (de) | Peptide des menschlichen proteins p53 zum gebrauch in menschlichen-zytotoxischen-t-zell- antwort-induzierenden kompositionen sowie menschliche p53-protein-spezifische t-lymphocyten | |
BR9914066A (pt) | Polipeptìdio degradador de c3 de complemento humano de streptococcus pneumoniae | |
DK0494294T3 (da) | Bakterielle stressproteiner | |
HUP9901688A2 (hu) | A diabétesz kezelésére szolgáló, humán hősokk protein 60-ból származó új peptidek, készítmények, eljárások és kitek | |
NO952385D0 (no) | Fremgangsmåte til identifisering av individer med unormale celler som uttrykker HLA-A2/tyrosinasepeptidantigen | |
DK109280A (da) | Tripeptider og fremgangsmaade til fremstilling deraf | |
Southan et al. | Amino acid sequence of β‐galactoside‐binding bovine heart lectin: Member of a novel class of vertebrate proteins | |
NO963487L (no) | Isolerte, tyrosinaseavledete peptider, samt anvendelser derav | |
CA2351558A1 (en) | Peptide fragments having cell death inhibitory activity | |
WO1996018646A3 (en) | Heat shock protein peptides and methods for modulating autoimmune central nervous system disease | |
BR0309921A (pt) | Toxina relacionada a polipetìdeos, peptìdeo-mimético, anticorpo e ácido nucléico com atividade antimicrobiana e antiviral, bem como seu processo de preparação, sua composição farmacêutica e fabricação do medicamento | |
ES2145061T3 (es) | Diagnostico y terapia a base de peptidos para el tratamiento de las espondiloartropatias. | |
DE69326145T2 (de) | Synthetische peptide für die behandlung von myasthenia gravis | |
KR950032277A (ko) | 신규의 폴리펩티드 및 그것을 암호화하는 디엔에이(dna) | |
Milstein | The heterogeneity of human immunoglobulins. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 0751957 Country of ref document: EP |
|
REN | Ceased due to non-payment of the annual fee |